AstraZeneca said on Monday their vaccine for the coronavirus, developed along with the University of Oxford, showed an average efficiency of 70 per cent in protecting against the virus in two study segments.
Two dosing processes were tested. In the first test, participants were administered a half dose, followed one month later by a full dose, with the vaccine was found to be 90 per cent effective. In a second dosing schedule, two full doses were administered one month apart, resulting in 62 per cent efficacy. The average of both dosing regimens was 70 per cent.
No hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.
“This vaccine’s efficacy and safety confirm that it will be highly effective against Covid-19, and it will have an immediate impact on this public health emergency,” Pascal Soriot, Astra’s chief executive, said in a statement.
This British drugmaker will immediately prepare to apply for conditional or early approval. This company will also seek an approval from the World Health Organisation for using the vaccine in low-income countries.